Abuhandan M, Calik M, Almaz V, Taskın A, Cakmak A, Selek S
Department of Pediatrics, Faculty of Medicine, Harran University, Sanliurfa, Turkey.
Clin Ter. 2013 May-Jun;164(3):e159-62. doi: 10.7417/CT.2013.1561.
This study aimed to evaluate the neuropeptide Y values of patients with subacute sclerosing panencephalitis.
The study comprised 38 patients diagnosed with subacute sclerosing panencephalitis at our clinic, who were being routinely followed-up, together with a control group of 36. Using the Risk and Haddad classification for clinical staging, 16 patients were determined as Stage II and 22 patients as Stage III. Neuropeptide Y values were measured by Enzyme Immunoassay methods.
The neuropeptide Y values of the all patients with subacute sclerosing panencephalitis were found to be significantly high compared to the control group (p<0.01). The neuropeptide Y values of the Stage III group were found to be significantly high compared to the Stage II and control groups (p<0.05). The neuropeptide Y values of the Stage II group were not determined to be significant compared to the control group (p≤0.05).
Neuropeptide Y can be considered a useful parameter to confirm diagnosis at advanced stages and to establish differences between stages in patients with subacute sclerosing panencephalitis.
本研究旨在评估亚急性硬化性全脑炎患者的神经肽Y值。
本研究纳入了在我院门诊确诊为亚急性硬化性全脑炎且正在接受常规随访的38例患者，以及36例对照组患者。采用Risk和Haddad临床分期分类法，16例患者被确定为II期，22例患者为III期。通过酶免疫测定法测量神经肽Y值。
与对照组相比，所有亚急性硬化性全脑炎患者的神经肽Y值均显著升高（p<0.01）。与II期和对照组相比，III期组的神经肽Y值显著升高（p<0.05）。与对照组相比，II期组的神经肽Y值无显著差异（p≤0.05）。
神经肽Y可被视为亚急性硬化性全脑炎患者晚期确诊及区分不同分期的有用参数。
